VVN461 Ophthalmic Solution 1.0%

DRUG4 trials

Sponsors

VivaVision Biotech, Inc

Conditions

Anterior UveitisHealthy VolunteersInflammationNon-infectious Anterior Uveitis

Phase 1

Pharmacokinetics of VVN461 Ophthalmic Solution

CompletedNCT06906198

VivaVision Biotech, IncHealthy Volunteers

Start: 2023-03-01End: 2023-12-22Updated: 2025-04-02

Phase 2

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

CompletedNCT06164743

VivaVision Biotech, IncInflammation

Start: 2024-01-11End: 2024-05-15Updated: 2026-09-11

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

CompletedNCT06679153

VivaVision Biotech, IncAnterior Uveitis

Start: 2023-11-27End: 2024-12-29Updated: 2025-01-27

Phase 3

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

Active, not recruitingNCT07136805

VivaVision Biotech, IncNon-infectious Anterior Uveitis

Start: 2025-11-25End: 2027-04-30Updated: 2026-08-24